Paraoxon has only a minimal effect on pralidoxime brain concentration in rats

Journal of Applied Toxicology

Volumn 27, Issue 4, 2007, Pages 350-357

  Petroianu, George A ^a   Lorke, D E ^a,b   Hasan, M Y ^a   Adem, A ^a   Sheen, R ^a   Nurulain, S M ^a   Kalasz, H ^c  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF HAMBURG   (Germany)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Blood brain barrier; HPLC; Organophosphate; Oxime; Paraoxon; Pralidoxime

Indexed keywords

PARAOXON; PRALIDOXIME; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; BRAIN; CHOLINESTERASE INHIBITORS; CHOLINESTERASE REACTIVATORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; MALE; MOLECULAR STRUCTURE; PARAOXON; PERFUSION; PRALIDOXIME COMPOUNDS; RATS; RATS, WISTAR; SPECIES SPECIFICITY; VASODILATION;

ANIMALIA; RATTUS;

EID: 34447558022     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1213     Document Type: Article

References (29)

1. Bajgar J. 2004. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem. 38: 151-216.
2. Bodor N, Shek E, Higuchi T. 1975. Delivery of a quaternary pyridinium salt across the blood-brain barrier by its dihydropyridine derivative. Science 190 (4210): 155-156.
3. Buckley N, Eddleston M, Szinicz L. 2005. Oximes for acute organophosphate pesticide poisoning. Cochrane Database Syst. Rev. 1: CD005085.
4. Cabal J, Kuca K, Kassa J. 2004. Specification of the structure of oximes able to reactivate tabun-inhibited acetylcholinesterase. Basic Clin. Pharmacol. Toxicol. 95: 81-86.
5. Dart RC, Goldfrank LR, Chyka PA, Lotzer D, Woolf AD, McNally J, Snodgrass WR, Olson KR, Scharman E, Geller RJ, Spyker D, Kraft M, Lipsy R. 2000. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann. Emerg. Med. 36: 126-132.
6. Eddleston M, Szinicz L, Eyer P, Buckley N. 2002. Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials. QJM 95: 275-283.
7. 14 into brain and the effect of cholinesterase inhibitors on its transport. J. Pharmacol. Exp. Ther. 145: 252-265.
8. Jeevarathinam K, Ghosh AK, Srinivasan A, Das Gupta S. 1988. Pharmakokinetics of Pralidoxime chloride and its correlation to therapeutic efficacy against diisopropyl fluorophosphate intoxication in rats. Pharmazie 43: 114-115.
9. Julien-Dolbec C, Tropres I, Montigon O, Reutenauer H, Ziegler A, Decorps M, Payen JF. 2002. Regional response of cerebral blood volume to graded hypoxic hypoxia in rat brain. Br. J. Anaesth. 89: 287-293.
10. Kassa J. 2002. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J. Toxicol. Clin. Toxicol. 6: 803-816.
11. Kuča K, Jun D, Musilek K. 2006. Structural requirements for acetylcholinesterase reactivators. Mini Rev. Med. Chem. 6: 269-277.
12. Luettringhaus A, Hagedorn I. 1964. Quaternary hydroxyiminomethyl- pyridinium salts, the dischloride of bis-(4-hydroxyiminomethyl-1-pyridinium- methyl)-ether (lueh6), a new reactivator of acetylcholinesterase inhibited by organic phosphoric acid esters. Arzneimittelforschung 14: 1-5.
13. Peter V, Moran JL, Graham P. 2006. Oxime therapy and outcomes in human organophosphate poisoning: An evaluation using metaanalytic techniques. Crit. Care Med. 34: 502-510.
14. Petroianu GA, Arafat K, Kuca K, Kassa J. 2006a. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acetylcholinesterase inhibited by paraoxon. J. Appl. Toxicol. 26: 64-71.
15. Petroianu GA, Arafat K, Schmitt A, Hasan MY. 2005a. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J. Appl. Toxicol. 25: 60-67.
16. Petroianu GA, Arafat K, Schmitt A, Hasan MY. 2005b. Weak inhibitors protect cholinesterases from strong inhibitors (dichlorvos): in vitro effect of tiapride. Int. J. Toxicol. 24: 79-86.
17. Petroianu G, Hardt F, Toomes M, Bergler W, Rüfer R. 2001. High-dose intravenous paraoxon exposure does not cause organophosphate induced delayed neuropathy (OPIDN) in mini pigs. J. Appl. Toxicol. 21: 263-268.
18. Petroianu GA, Hasan MY, Arafat K, Nurulain SM, Schmitt A. 2005c. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of tiapride. J. Appl. Toxicol. 25: 562-567.
19. Petroianu GA, Missler A, Zuleger K, Thyes C, Ewald V, Maleck WH. 2004. Enzyme reactivator treatment in organophosphate exposure: the clinical relevance of thiocholine-esteratic activity of pralidoxime. J. Appl. Toxicol. 24: 429-435.
20. Petroianu GA, Nurulain SM, Nagelkerke N, Al-Sultan MA, Kuca K, Kassa J. 2006b. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon. J. Appl. Toxicol. 26: 262-268.
21. Reddy VK, Deshpande SS, Cintra WM, Scoble GT, Albuquerque EX. 1991. Effectiveness of oximes 2-PAM and HI-6 in recovery of muscle function depressed by organophosphate agents in the rat hemidiaphragm: an in vitro study. Fundam. Appl. Toxicol. 17: 746-760.
22. Rump S, Faff J, Borkowska G, Ilczuk I, Rabsztyn T. 1978. Central therapeutic effects of dihydroderivative of pralidoxime (pro-2-PAM) in organophosphate intoxication. Arch. Int. Pharmacodyn. Thér. 232: 321-332.
23. Sakurada K, Matsubara K, Shimizu K, Shiono H, Seto Y, Tsuge K, Yoshino M, Sakai I, Mukoyama H, Takatori T. 2003. Pralidoxime iodide (2-pAM) penetrates across the blood-brain barrier. Neurochem. Res. 28: 1401-1407.
24. Todd MM, Weeks JB, Warner DS. 1993. The infuence of intravascular volume expansion on cerebral blood flow and blood volume in normal rats. Anesthesiology 78: 945-953.
25. Tsuji A. 2005. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2: 54-62.
26. Tsukita S, Furuse M, Itoh M. 2001. Multifunctional strands in tight junctions. Nature Rev. Mol. Cell. Biol. 2: 285-293.
27. Turksen K, Troy TC. 2004. Barriers built on claudins. J. Cell. Sci. 117: 2435-2447.
28. Wilson IB, Ginsburg S. 1955. A powerful reactivator of alkylphosphate. Biochim. Biophys. Acta 18: 168-170.
29. Wolburg H, Lippoldt A. 2002. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc. Pharmacol. 38: 323-337.